Target Name: CD27-AS1
NCBI ID: G678655
Other Name(s): CD27 antisense RNA 1

CD27-AS1: A Promising Drug Target and Biomarker for Cancer Treatment

Abstract:
CD27-AS1 is a highly expressed gene in various tissues, including the brain, spleen, and lymph nodes. Its expression has been associated with various diseases, including cancer. CD27-AS1 has also been identified as a potential drug target and biomarker. In this article, we will discuss the biology of CD27-AS1, its expression patterns, potential drug targets, and its potential as a biomarker for cancer diagnosis and treatment.

Introduction:
CD27 is a costimulating molecule that plays a critical role in T cell activation and proliferation. Its expression has been implicated in various diseases, including cancer. CD27 has also been identified as a potential drug target and biomarker. CD27-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases, including cancer.

CD27-AS1 Expression:
CD27 is a glycoprotein that is expressed in various tissues, including the brain, spleen, and lymph nodes. Its expression has been associated with various diseases, including cancer. CD27 has been shown to be highly expressed in various types of cancer, including breast, lung, and ovarian cancer.

CD27-AS1 has also been shown to be expressed in various tissues and organs, including the brain, spleen, and lymph nodes. Its expression has been associated with various diseases, including cancer. CD27-AS1 has also been shown to be highly expressed in various types of cancer, including breast, lung, and ovarian cancer.

CD27-AS1 Potential Drug Target:
CD27 has been shown to play a critical role in T cell activation and proliferation. Its expression has been implicated in various diseases, including cancer. CD27 has also been identified as a potential drug target.

CD27 has been shown to play a critical role in T cell activation and proliferation. Its expression has been implicated in various diseases, including cancer. CD27 has also been identified as a potential drug target.

CD27-AS1 Potential Biomarker:
CD27-AS1 has been identified as a potential biomarker for cancer diagnosis and treatment. Its expression has been associated with various diseases, including cancer.

CD27 has been shown to play a critical role in T cell activation and proliferation. Its expression has been implicated in various diseases, including cancer. CD27-AS1 has been identified as a potential biomarker for cancer diagnosis and treatment.

Conclusion:
In conclusion, CD27-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases, including cancer. Its expression has been associated with various diseases, including cancer. Further research is needed to fully understand the role of CD27-AS1 as a drug target and biomarker for cancer treatment.

Protein Name: CD27 Antisense RNA 1

More Common Targets

CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1